Jasper reports more data in spontaneous hives from tiny study

Max Gelman

Senior Editor

Jasper Therapeutics continued building out the data for a drug designed to treat irritable skin conditions, though the latest results came from a small trial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Jasper reports more data in spontaneous hives from tiny study

Max Gelman

Senior Editor

Sign up to read this article for free.

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Gene editing startup Scribe Therapeutics lets go of staff as it preps for the clinic

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

Resilience cuts 120 employees at a former bluebird gene therapy site

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

Jasper re­ports more da­ta in spon­ta­neous hives from tiny study

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Gene edit­ing start­up Scribe Ther­a­peu­tics lets go of staff as it preps for the clin­ic

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

Re­silience cuts 120 em­ploy­ees at a for­mer blue­bird gene ther­a­py site

MaaT Phar­ma touts ‘un­prece­dent­ed’ Phase 3 ef­fi­ca­cy of graft-ver­sus-host dis­ease treat­ment

Jasper reports more data in spontaneous hives from tiny study

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Gene editing startup Scribe Therapeutics lets go of staff as it preps for the clinic

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

Resilience cuts 120 employees at a former bluebird gene therapy site

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment